Healthcare
Live Price
Offline$6.93
+2.51% today
1Y Change
+17.16%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silence Therapeutics plc (SLN) is a Healthcare stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $6.93 and up 17.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -98.7%, EPS growth of +20.3%, a dividend yield of 0.0%. What stands out right now is revenue -98.7%, EPS +20.3%, free cash flow +8.1% with operating margin -16292.8% and ROIC -77.3%. Valuation already assumes a fairly strong business story at price/sales 602.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLN Max Drawdown
-41.89%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.4M
-42.7% YoY
FY Net Income
-$39.4M
+21.7% YoY
Free Cash Flow
$7.4M
+112.8% YoY
Revenue Growth
-98.7%
EPS Growth
+20.3%
Gross Margin
61.5%
Net Margin
-15851.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 559K | 43M | 25M | 22M | 12M |
| Gross Profit | 344K | 31M | 15M | 8M | 5M |
| Operating Income | -82M | -63M | -50M | -61M | -46M |
| EBITDA | -89M | -49M | -50M | -60M | -45M |
| Net Income | -89M | -45M | -43M | -50M | -39M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 121M | 69M | 55M | 74M |
| Total Assets | 131M | 203M | 119M | 108M | 96M |
| Total Liabilities | 69M | 69M | 97M | 85M | 88M |
| Shareholder Equity | 62M | 134M | 22M | 22M | 9M |
| Total Debt | -160K | 117K | 346K | 446K | 137K |
| Net Debt | -11M | -121M | -68M | -54M | -73M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+116.1% YoY
Capital Expenditures
2M
-230.4% YoY
Free Cash Flow
7M
+112.8% YoY
Key ratios
Gross Margin
61.5%
Operating Margin
-16292.8%
Net Margin
-15851.9%
ROE
-300.9%
Debt / Equity
-0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.